89O BMS-986504 with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007

Read full text Summarise with VIRAT
Authors: B. George, Konstantinos Leventakos, M. Pelster, Jordi Ahnert Rodon, K.P. Papadopoulos, A. Spira, Kathryn Cecilia Arbour, C.A. Perez, Hani M. Babiker, Pasi Antero Janne, R.M Flores Zuniga, A.S. Paulson
+8 more Tanios Bekaii-Saab, S. Chandana, Mandana Kamgar, Lars D. Engstrom, Antonella Mazzei, Alicia Cheong, H. Shi, J. Henry
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In the phase 1 CA240-0007 study, BMS-986504 (MTA-cooperative PRMT5 inhibitor) was well tolerated and had antitumor activity in pts with MTAP-del advanced solid tumors, including PDAC. Here, we report updated clinical outcomes with BMS-986504 monotherapy and initial efficacy and safety data for BMS-986504 + GEM + nab-P in substudy 3 (SS3) of pts with PDAC.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Peptidase Inhibition and Analysis PARP inhibition in cancer therapy

Publication details

Journal / source
ESMO Open
Volume
11
Pages
106231–106231
Publication date
1 April 2026
Language
EN